1. Home
  2. PGP vs ELTX Comparison

PGP vs ELTX Comparison

Compare PGP & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Global StocksPlus & Income Fund of Beneficial Interest

PGP

Pimco Global StocksPlus & Income Fund of Beneficial Interest

HOLD

Current Price

$8.75

Market Cap

102.9M

Sector

Finance

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$10.71

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGP
ELTX
Founded
2003
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.9M
185.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
PGP
ELTX
Price
$8.75
$10.71
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
30.3K
132.9K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
10.84%
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.82
$5.80
52 Week High
$9.41
$14.93

Technical Indicators

Market Signals
Indicator
PGP
ELTX
Relative Strength Index (RSI) 39.86 47.92
Support Level $8.42 $9.97
Resistance Level $8.94 $11.47
Average True Range (ATR) 0.15 0.87
MACD -0.05 -0.01
Stochastic Oscillator 20.49 28.81

Price Performance

Historical Comparison
PGP
ELTX

About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest

PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: